Resistance to activated protein C and Legg-Perthes disease

Clinical Orthopaedics and Related Research

Volumn 338, Issue , 1997, Pages 139-152

  Glueck, Charles J ^a   Brandt, Greg ^b   Gruppo, Ralph ^b   Crawford, Alvin ^b   Roy, Dennis ^b   Tracy, Trent ^a   Stroop, Davis ^a   Wang, Ping ^a   Becker, Ann ^b  

^a JEWISH HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHLORIDE; PROTEIN C;

ARTICLE; BLOOD CLOTTING; CHILD; DNA DETERMINATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PATHOGENESIS; PERTHES DISEASE; PRIORITY JOURNAL; THROMBOPHILIA; VEIN OCCLUSION; VERTICAL TRANSMISSION;

EID: 0030946951     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-199705000-00021     Document Type: Article

References (27)

1. Bertina RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67, 1994.
2. Boettcher WG, Bonfiglio H, Hamilton HH, Sheets RF, Smith K: Non traumatic osteonecrosis of the femoral head: 1. Relation of altered hemostasis to etiology. J Bone Joint Surg 52A:312-321, 1970.
3. Choi D, Lee DY, Chung CY, Rhyu KH, Park SY: Changes in coagulation-fibrinolysis system in Legg-Perthes disease: A preliminary report. Proc Pediatr Orthop Soc North Am 2:1. 1995. Abstract.
4. Dahlback B: Physiological anticoagulation: Resistance to activated protein C and venous thromboembolism. J Clin Invest 94:923-927, 1994.
5. Glueck CJ, Crawford A, Roy D, et al: Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg Perthes disease. J Bone Joint Surg 78A:3-13, 1996.
6. Glueck CJ, Freiberg R, Glueck HI, et al: Hypofibrinolysis: A common, major cause of osteonecrosis. Am J Hematology 45:156-166, 1994.
7. Glueck CJ, Freiberg R, Glueck HI, et al: Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high Lp (a), and therapy with Stanozolol. Am J Hematology 48:213-220, 1995.
8. Glueck CJ, Freiberg R, Tracy T, Stroop D, Wang P: Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop 334:43-56, 1997.
9. Glueck CJ, Glueck HI, Greenfield D, et al: Protein C and S deficiency, thrombophilia, and hypofibrinolysis: Pathophysiologic causes of Legg-Perthes disease. Pediatr Res 35:383-388, 1994.
10. Glueck CJ, Glueck HI, Tracy T, et al: Relationships between lipoprotein (a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and d-dimer. Metabolism 42:236-246, 1993.
11. Glueck CJ, McMahon RE, Bouquot J, et al: Pathophysiology of osteonecrosis of the jaw: Thrombophilia and hypofibrinolysis. Oral Surg Oral Med Oral Pathol 81:557-566, 1996.
12. Greengard JS, Eichinger S, Griffin JH, Bauer KA: Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg - Gln mutation in the gene for factor V. N Engl J Med 331:1559-1562, 1994.
13. Griffin JH, Evatt B, Wideman C, Fernandez JA: Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82:1989-1993, 1993.
14. Gruppo R, Glueck CJ, McMahon RE, et al: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis: Pathophysiology of osteonecrosis of the jaw. J Lab Clin Med 127:481-488, 1996.
15. Hajjar KA: Factor V Leiden-An unselfish gene? N Engl J Med 331:1585-1587, 1994.
16. Hall DJ: Genetic aspects of Perthes disease: A critical review. Clin Orthop 209:100-114, 1986.
17. Jenny RJ, Pittman DD, Toole JJ, et al: Complete DMA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 84:4846-1850, 1987.
18. Koeleman PC, Reitsma PH, Allan CF, Bertina RM: Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 84:1031-1035, 1994.
19. Lindblom B, Holmlund G: Rapid DNA purification for restriction fragment length polymorphism analysis. Gene Anal Technol 5:97-101, 1988.
20. Nagasawa F, Ishii Y, Mayumi T, et al: Avascular necrosis of bone in systemic lupus erythematosus: Possible role of hemostatic abnormalities. Ann Rheum Dis 48:672-676, 1989.
21. Nilsson IM, Krook H, Sternby HH, Soderberg E, Soderstrom N: Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta Med Scand 169:323-327, 1961.
22. Ridker PM, Hennekens CH, Lindpaintner K, et al: Mutation in the gene coding for coagulation factor V and the risk myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912-917, 1995.
23. Rosendaal FR, Koster T, Vandenbroucke JP, Rietsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504-1508. 1995.
24. Shen L, Dahlback B: Factor V and protein 8 as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 22:18735-18738, 1994.
25. Van Veldhuizen RI, Neff J, Murphey MD, Bodensteiner B, Skikne BS: Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematology 44:243-248, 1993.
26. Voorberg J, Roelse J, Koopman R, et al: Association of idiopathic venous thromboembolism with single point-mutation at Arc 506 of factor V. Lancet 343: 1535-1536, 1994.
27. Zoller B, Svensson PJ, He X, Dahlback E: Identification of the same factor V gene mutation in 47 of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94: 2521-2524, 1994.